DNA Q2 2023 Earnings — Ginkgo Bioworks Holdings, Inc. Revenue & Financial Results | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

$418M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$81M-44.3% YoY

Gross Profit

$62M77.5% margin

Operating Income

-$184M-228.6% margin

Net Income

-$173M-215.1% margin

EPS (Diluted)

$-3.60

QoQ Revenue Growth

-0.2%

Cash Flow

Operating Cash Flow

-$74M

Free Cash Flow

-$87M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$788M

Stockholders' Equity

$1.5B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$81M	$145M	-44.3%
Gross Profit	$62M	$81M	-22.6%
Operating Income	-$184M	-$648M	+71.6%
Net Income	-$173M	-$669M	+74.1%

Revenue Segments

Service

$24M69%

Product

$11M31%